As GLP-1 medications like Ozempic and Mounjaro gain popularity for managing diabetes and obesity, it's crucial to understand their nutritional implications. This article explores the potential side effects of these medications, including gastrointestinal issues and nutritional d…
A recent study from Virginia Tech has found that ultra-processed foods can lead to a significantly higher insulin response compared to less processed meals, even when both meals c…
Eli Lilly's experimental obesity treatment, combining eloralintide and Mounjaro, has demonstrated an average weight loss of 23% in individuals with diabetes, highlighting its pote…
Recent clinical trial data reveals that Retatrutide, a new obesity treatment, resulted in an average weight loss of 25% after 80 weeks and 30% after 104 weeks among participants.…
Eli Lilly's GLP-1 drug retatrutide has demonstrated remarkable efficacy in aiding individuals with Type 2 diabetes to lose up to 60 pounds, or about 23% of their body weight, acco…
Roche has reported promising results from its mid-stage trial of enicepatide, an obesity drug that helped patients with type 2 diabetes achieve an average weight loss of 15.5% and…
A recent analysis reveals that prescription rates for GLP-1 weight-loss medications, such as Wegovy and Mounjaro, are significantly lower in England's most deprived areas, despite…
The FDA has granted approval for Mounjaro (tirzepatide) to reduce cardiovascular risk in individuals with type 2 diabetes, marking a significant development in diabetes management…
The FDA has approved Eli Lilly's medication Mounjaro for reducing the risk of heart events in individuals with Type 2 diabetes. This approval adds to the drug's existing use for b…
As the popularity of weight-loss drugs like GLP-1 receptor agonists grows, a black market for the unapproved drug retatrutide has emerged, alarming health experts. Developed by El…
As obesity medications evolve, researchers are exploring new hormone combinations to enhance treatment effectiveness and tolerability. Current studies focus on therapies that not…
This article examines how GLP-1 and GIP agonist medications influence 'food noise,' defined as intrusive thoughts about food, and their implications for weight loss and eating beh…